BOKF NA decreased its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 80.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,686 shares of the biotechnology company’s stock after selling 11,045 shares during the period. BOKF NA’s holdings in Sarepta Therapeutics were worth $293,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in the company. Cornerstone Advisors Inc. bought a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $25,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $51,000. Larson Financial Group LLC bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $55,000. Ffcm LLC raised its holdings in Sarepta Therapeutics by 31.1% in the fourth quarter. Ffcm LLC now owns 1,311 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 311 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Sarepta Therapeutics by 168.3% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 1,610 shares of the biotechnology company’s stock worth $175,000 after purchasing an additional 1,010 shares in the last quarter. Hedge funds and other institutional investors own 95.66% of the company’s stock.
Shares of SRPT traded up $2.28 during midday trading on Monday, reaching $119.77. The company had a trading volume of 1,023,933 shares, compared to its average volume of 1,320,217. The company has a market capitalization of $8.41 billion, a PE ratio of -21.94 and a beta of 2.04. The company has a quick ratio of 7.49, a current ratio of 8.21 and a debt-to-equity ratio of 0.41. Sarepta Therapeutics Inc has a 1-year low of $74.51 and a 1-year high of $176.50.
In related news, CFO Sandesh Mahatme sold 65,000 shares of the firm’s stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $145.00, for a total transaction of $9,425,000.00. Following the completion of the transaction, the chief financial officer now directly owns 73,649 shares in the company, valued at approximately $10,679,105. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David T. Howton sold 30,000 shares of the firm’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $140.00, for a total value of $4,200,000.00. Following the transaction, the senior vice president now owns 31,196 shares of the company’s stock, valued at $4,367,440. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 160,000 shares of company stock valued at $22,089,950. Company insiders own 7.90% of the company’s stock.
A number of equities analysts have commented on SRPT shares. HC Wainwright set a $267.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Friday, January 4th. BMO Capital Markets began coverage on Sarepta Therapeutics in a research report on Tuesday, March 12th. They issued an “outperform” rating on the stock. Morgan Stanley upped their target price on Sarepta Therapeutics from $161.00 to $169.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $164.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, January 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $191.14.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Featured Story: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.